David Ambinder, MD

David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.

Articles by David Ambinder, MD

David Ambinder, MDUpper Tract Urothelial Carcinoma | May 31, 2023
There are 7 recommendations specific to the appropriateness of and proper technique for kidney-sparing management.
Read More
David Ambinder, MDUpper Tract Urothelial Carcinoma | May 30, 2023
The recent AUA/SUO guideline on the management of non-metastatic UTUC includes 2 recommendations for lymph node dissection.
David Ambinder, MDAUA 2023 | May 2, 2023
Drs. David Ambinder and Akhil Saji highlight the importance of attending the AUA meeting as urology residents.
David Ambinder, MDUpper Tract Urothelial Carcinoma | May 1, 2023
A retrospective study investigated the efficacy of UGN-101 as an adjuvant therapy after complete endoscopic tumor ablation.
Kristen Scarpato, MD, MPHAUA 2023 | May 1, 2023
Dr. Ambinder interviews Dr. Scarpato on when focal therapy should be recommended as salvage therapy for BCR prostate cancer.
David Ambinder, MDNon-Muscle Invasive Urothelial Carcinoma | April 26, 2023
Is there an alternative regimen to BCG for NMIBC? The combination of intravesical gemcitabine and docetaxel may be.
David Ambinder, MDLocalized Prostate Cancer | April 26, 2023
The recent ProtecT analysis examined 15-year follow-up data on mortality, metastasis-free survival, and disease progression.
David Ambinder, MDProstate Cancer | March 31, 2023
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
David Ambinder, MDProstate Cancer | March 31, 2023
Cryotherapy as a concept has been discussed since the 2000s. Yet randomized trials for the use of focal therapy are lacking.
David Ambinder, MDProstate Cancer | March 24, 2023
Can using a hyaluronic acid spacer mitigate rectal toxicity and reduce the gastrointestinal toxicity associated with RT?
David Ambinder, MDProstate Cancer | February 23, 2023
It is increasingly common for patients with favorable intermediate-risk PC to be managed with active surveillance.
David Ambinder, MDProstate Cancer | February 23, 2023
Implementing sterilization techniques may reduce infectious complications associated with transrectal prostate biopsy.
David Ambinder, MDmHSPC | February 23, 2023
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
David Ambinder, MDRenal Cell Carcinoma | January 18, 2023
Cytoreductive nephrectomy is controversial in the metastatic RCC setting, especially in the age of immunotherapy.
David Ambinder, MDLocalized Prostate Cancer | January 18, 2023
With a lack of trials that address different surgical options for localized PC, is there evidence to guide patients?
David Ambinder, MDProstate Cancer | January 18, 2023
A recent review provides evidence of room for improvement in racial, ethnic group representation in clinical trials.
David Ambinder, MDJournal | December 19, 2022
Upfront cytoreductive nephrectomy for patients with MRCC with immune checkpoint inhibitors or targeted therapy is examined.
David Ambinder, MDJournal | December 19, 2022
According to a recent study published in The Lancet Oncology, radiation may offer safety and long-term efficacy for RCC.
David Ambinder, MDJournal | December 19, 2022
By administering immediate single-dose intravesical chemotherapy, there is a 15% absolute risk reduction in tumor recurrence.
David Ambinder, MDJournal | November 22, 2022
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.